“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care. The company develops a long line of blockbuster glucagon-like ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

In this story, we're highlighting each of the amendments, and we're offering the recommendations (when available) of the editorial boards of two Florida newspapers in the USA TODAY NETWORK and four ...

The move to Miami came after two residencies in Florida. Samoylova is still shooting in Florida; her boat tour of New York last month was a stop on a long journey up the East Coast for a new project.

A Republican and Democrat came together Friday to criticize Florida Gov. Ron DeSantis' administration spending millions of taxpayer dollars on advertisements they say illegally target the ...

A US Senate panel, led by senator Bernie Sanders, has urged Novo Nordisk to lower the list prices for its obesity and diabetes drugs, the two areas from which the group earns the bulk of its profits.

On October 11, 2024, a Florida federal court approved a consent decree between the U.S. Equal Employment Opportunity Commission (EEOC) and Lago Mar Properties Inc. This settlement marks one of the ...

Novo Nordisk's blockbuster diabetes drug Ozempic ... but they want to wait one or two years for GLP-1s approved for weight loss to be on the market longer so there is more patient data for them ...